Why the study?
Severe aortic stenosis and wild-type transthyretin cardiac amyloidosis frequently coexist in elderly patients referred for TAVR and carry a worse prognosis.
Highlights the importance of recognizing concomitant wild-type transthyretin cardiac amyloidosis in elderly patients with severe aortic stenosis, as it impacts prognosis and management.
Concomitant ATTRwt CA in severe AS may worsen prognosis; leaves open whether screening or tailored therapy improves outcomes in elderly patients.
Degenerative aortic valve (AV) disease is the most frequent valvular heart disease slowly progressing to severe aortic stenosis (AS) which usually requires aortic valve replacement. Another frequent condition, especially among elderly people, is cardiac amyloidosis (CA), particularly the wild-type transthyretin cardiac amyloidosis (ATTRwt). Since both of these diseases are considered a marker of ageing, there is a significant proportion of elderly patients who associate both severe AS and CA. Recent studies reported a high prevalence of both severe AS and CA (AS-CA) in elderly patients referred for TAVR of 13-16%, carrying a worse prognosis. The present case illustrates the diagnostic algorithm and the management of ATTRwt CA in an elderly patient with severe paradoxical low-flow low-gradient AS, accompanied by a review of the current literature about the red flags which help identifying CA in patients with severe AS, as well as the prognosis and management of these disease association.
No takes yet. Share an insight, caveat, or question.
Adam et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: